Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors
Immunome announced the first patient dosing in the Phase 1, first-in-human trial of IM-1617, a potential first-in-class antibody-drug conjugate (ADC) for advanced solid tumors. IM-1617 incorporates Immunome’s proprietary HC74 topoisomerase I inhibitor payload and targets an undisclosed receptor tyrosine kinase. The open-label, multicenter study will evaluate safety, tolerability, and preliminary anti-tumor activity in patients with colorectal, lung, and breast cancers.
Key figures
- Drug Name
- IM-1617
- Phase Of Trial
- Phase 1
- Payload
- HC74
- Mechanism
- TOP1 inhibitor
- Asset type
- ADC
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.